Our exploratory analyses suggest that higher relative abundance of peripheral CD3+ cells and lower relative abundance of CD8+ cells were associated with SMI loss, and a low proportion of CD8+ TIL was protective against SMI loss during treatment of advanced lung cancer patients receiving immunotherapy. Here, CD8A is linked to lung cancer.